לקוסמיד טבע 150 מג
abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 150 mg - lacosamide
לקוסמיד טבע 200 מג
abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 200 mg - lacosamide
לקוסמיד טבע 50 מג
abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 50 mg - lacosamide
לקוסמיד טבע 100 מג
abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 100 mg - lacosamide
ביאוביו 120מגמל
novartis israel ltd - brolucizumab - תמיסה להזרקה - brolucizumab 120 mg / 1 ml - brolucizumab
פולבניר
bioavenir ltd, israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant
פייקומפה תרחיף לשתיה
eisai israel ltd., israel - perampanel as anhydrous - תרחיף - perampanel as anhydrous 0.5 mg / 1 ml - perampanel
נובוסבן אר.טי 1 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 2 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 5 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.